Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
about
Oral Apremilast for the Treatment of Plaque PsoriasisThe immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities.Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
P2860
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@ast
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@en
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@nl
type
label
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@ast
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@en
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@nl
prefLabel
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@ast
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@en
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@nl
P2860
P921
P3181
P356
P1476
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
@en
P2093
Giampiero Girolomoni
P2860
P304
P3181
P356
10.2147/DDDT.S108115
P407
P5008
P577
2016-05-25T00:00:00Z